Boris Reva

Boris Reva

Auto-generated profile, based on publicly available information

Boris Reva

Department of Genetics and Genomic Sciences, Icahn School of Medicine at Mount Sinai, New York, NY 10029, USA

Research Focus & Metrics

Academic Career Length

36Years (1991-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 May 2012 in Cancer Discovery
Verified
Journal Article
Closed access
PDF file
ECEthan Cerami
Ethan Cerami
JGJianjiong Gao
Jianjiong Gao
UDUgur Dogrusoz
Ugur Dogrusoz
BGBenjamin E. Gross
Benjamin E. Gross
SSSelcuk Onur Sumer
Selcuk Onur Sumer
NSNikolaus Schultz
Nikolaus Schultz
The cBio Cancer Genomics Portal (http://cbioportal.org) is an open-access resource for interactive exploration of multidimensional cancer genomics data sets, currently providing access to data from more than 5,000 tumor samples from 20 cancer studies. The cBio Cancer Genomics Portal significantly lowers the barriers between complex genomic data and cancer researchers who want rapid, intuitive, and high-quality access to molecular profiles and clinical attributes from large-scale cancer genomics projects and empowers researchers to translate these rich data sets into biologic insights and clinical applications. Cancer Discov; 2(5); 401–4. ©2012 AACR.

1 July 2010 in Cancer Cell
Verified
Journal Article
Closed access
BTBarry S. Taylor
Barry S. Taylor
NSNikolaus Schultz
Nikolaus Schultz
HHHaley Hieronymus
Haley Hieronymus
AGAnuradha Gopalan
Anuradha Gopalan
YXYonghong Xiao
Yonghong Xiao
WGWilliam L. Gerald
William L. Gerald

3 July 2011 in Nucleic Acids Research
Verified
Journal Article
Open access
PDF file
BRBoris Reva
Boris Reva
YAYevgeniy Antipin
Yevgeniy Antipin
CSChris Sander
Chris Sander
As large-scale re-sequencing of genomes reveals many protein mutations, especially in human cancer tissues, prediction of their likely functional impact becomes important practical goal. Here, we introduce a new functional impact score (FIS) for amino acid residue changes using evolutionary conservation patterns. The information in these patterns is derived from aligned families and sub-families of sequence homologs within and between species using combinatorial entropy formalism. The score performs well on a large set of human protein mutations in separating disease-associated variants (∼19 200), assumed to be strongly functional, from common polymorphisms (∼35 600), assumed to be weakly functional (area under the receiver operating characteristic curve of ∼0.86). In cancer, using recurrence, multiplicity and annotation for ∼10 000 mutations in the COSMIC database, the method does well in assigning higher scores to more likely functional mutations (‘drivers’). To guide experimental prioritization, we report a list of about 1000 top human cancer genes frequently mutated in one or more cancer types ranked by likely functional impact; and, an additional 1000 candidate cancer genes with rare but likely functional mutations. In addition, we estimate that at least 5% of cancer-relevant mutations involve switch of function, rather than simply loss or gain of function.

5 June 2011 in Nature Genetics
Verified
Journal Article
Closed access
PDF file
MBMatthew Bott
Matthew Bott
MBMarie Brevet
Marie Brevet
BTBarry S Taylor
Barry S Taylor
SSShigeki Shimizu
Shigeki Shimizu
TITatsuo Ito
Tatsuo Ito
MLMarc Ladanyi
Marc Ladanyi

4 July 2010 in Nature Genetics
Verified
Journal Article
Open access
PDF file
JBJordi Barretina
Jordi Barretina
BTBarry S Taylor
Barry S Taylor
SBShantanu Banerji
Shantanu Banerji
ARAlexis H Ramos
Alexis H Ramos
MLMariana Lagos-Quintana
Mariana Lagos-Quintana
SSSamuel Singer
Samuel Singer
Samuel Singer and colleagues report an integrative genomic analysis of soft-tissue sarcomas. They survey sequence, copy number and mRNA expression in 207 individuals diagnosed with one of seven major high-grade sarcoma subtypes, and highlight subtype-specific alternations. Soft-tissue sarcomas, which result in approximately 10,700 diagnoses and 3,800 deaths per year in the United States1, show remarkable histologic diversity, with more than 50 recognized subtypes2. However, knowledge of their genomic alterations is limited. We describe an integrative analysis of DNA sequence, copy number and mRNA expression in 207 samples encompassing seven major subtypes. Frequently mutated genes included TP53 (17% of pleomorphic liposarcomas), NF1 (10.5% of myxofibrosarcomas and 8% of pleomorphic liposarcomas) and PIK3CA (18% of myxoid/round-cell liposarcomas, or MRCs). PIK3CA mutations in MRCs were associated with Akt activation and poor clinical outcomes. In myxofibrosarcomas and pleomorphic liposarcomas, we found both point mutations and genomic deletions affecting the tumor suppressor NF1. Finally, we found that short hairpin RNA (shRNA)-based knockdown of several genes amplified in dedifferentiated liposarcoma, including CDK4 and YEATS4, decreased cell proliferation. Our study yields a detailed map of molecular alterations across diverse sarcoma subtypes and suggests potential subtype-specific targets for therapy.

1 January 2009 in Cell Stem Cell
Verified
Journal Article
Closed access
YLYan Liu
Yan Liu
SEShannon E. Elf
Shannon E. Elf
YMYasuhiko Miyata
Yasuhiko Miyata
GSGoro Sashida
Goro Sashida
YLYuhui Liu
Yuhui Liu
SNStephen D. Nimer
Stephen D. Nimer